"Cocktail" Helps Adult Stem Cells Thrive in Lab

By Amanda Gardner, HealthDay Reporter

Scientists have discovered a "cocktail" of growth factors that expands the number of stem cells they can grow in the laboratory at least 10 times beyond what anyone has been able to do before...

23/01/2006

Read more

5 Spanish centers join a study for a new leukemia and lymphoma treatment technique

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit...

03/06/2009

Read more

Cord blood stem cell transplant hopes lifted

BBC News

A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time. It is hoped that "master cells" taken from umbilical cords could be used on any patient without rejection...

Read more

Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells|Lifeline

Ko K. Maung 1 Mitchell E. Horwitz 2

 

Ko K. Maung

KoKo.Maung@duke.edu

 

Mitchell E. Horwitz

Mitchell.Horwitz@duke.edu

 

1 Hematology and Medical Oncology Fellow, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC 27710, USA

2 Adult Blood and Marrow Transplant Program, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC 27710, USA

Read more

Expanded cord blood cells hold hope for leukemia patients

 

Clinical Research Division scientists have cleared a major technical hurdle to making umbilical cord blood transplants a more widely used method for treating leukemia and other blood cancers.

 

In a study published in the Jan. 17 edition of Nature Medicine, Dr. Colleen Delaney and colleagues describe the first use of a method to vastly expand the number of stem/progenitor cells from a unit of cord blood in the laboratory. When the cells were infused into patients, successful and rapid engraftment resulted.

 

Read more

First Patient Undergoes Expanded Cord Blood Transplant

The Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells...

Read more

Pluristem Announces Breakthrough in Bone Marrow Transplants: Engrafted Cells Increase 2-4 Times in Preclinical Study

HAIFA, Israel (BUSINESS WIRE)

Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced promising initial results of an animal model study using the company's innovative adjuvant cell therapy product known as PLX-1. PLX-1, by adding Mesenchymal Stromal Cells (MSC) during bone marrow transplant procedures that use...

05/07/2006

Read more

Scientists Triple Life-Saving Stem-Cell Production

Margaret Munro, CanWest News Service, Edmonton Journal

A life-saving stem-cell treatment has been given a boost by Canadian scientists, who've hit on a way to enhance production of the fabled cells. The team at the University of Western Ontario has shown an experimental drug can expand populations of stem cells in umbilical cord blood up to three times...

12/12/2005

Read more

USC And Childrens Hospital Los Angeles Researchers Discover A Way To Enhance The Growth Of Stem Cells From Umbilical Cord Blood After Transplantation

Medical News Today

Researcher-scientists at The Saban Research Institute of Childrens Hospital Los Angeles have discovered a way to dramatically enhance the growth of stem cells from umbilical cord blood after transplantation, according to Gay Crooks, M.B., B.S., director of the Stem Cell Project at Childrens Hospital Los Angeles and a professor of pediatrics at the Keck School of Medicine of the University of Southern California (USC)...

Read more

ViaCell Announces Completion Of CB001 Phase I Clinical Trial

ViaCell, Inc. (Nasdaq: VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option for people who need stem cell transplants, such as bone marrow, for hematopoietic recovery after...

25/07/2006

Read more